Abich Financial Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Abich Financial Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$61.9K	Buy	+932	New	+$53K	0.02%	289

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Abich Financial Wealth Management's PTGX Position: Q3 2025 in Review

Abich Financial Wealth Management opened a new position in Protagonist Therapeutics (PTGX) in Q3 2025: 932 shares worth $61.9K. The stake represents 0.02% of the portfolio and ranks #289 among its holdings.

275 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

Abich Financial Wealth Management held 932 shares of Protagonist Therapeutics worth $61.9K as of Q3 2025.
Protagonist Therapeutics was a new Abich Financial Wealth Management position in Q3 2025.
Protagonist Therapeutics made up 0.02% of Abich Financial Wealth Management's portfolio in Q3 2025, its #289 holding.
275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Abich Financial Wealth Management's 13F filing for Q3 2025, filed 6 Nov 2025.